[1]LIU J,MI R,CHEN L,et al.Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma:a meta-analysis of randomized controlled trials[J].Clinical and Experimental Medicine,2022,136(Supplement 1):13-14.
[2] CAZZOLA M.Introduction to a review series:the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues[J].Blood,2016,127(20):2375-2390.
[3] LENZ G,STAUDT LM.Aggressive lymphomas[J].N Engl J Med,2010,362(15):1417-1429.
[4] HARRINGTON F,GREENSLADE M,TALAULIKAR D,et al.Genomic characterisation of diffuse large B-cell lymphoma[J].Pathology,2021,53(3):367-376.
[5] HUET O,LAEMMEL E,FU Y,et al.Interleukin 10 antioxidant effect decreases leukocytes/endothelial interaction induced by tumor necrosis factor α[J].Shock,2013,39(1):83-88.
[6] 王玲玲,杨文秀,李逸,等.TNFAIP3 siRNA对弥漫大B细胞淋巴瘤 OCI-LY1 细胞NF-κB活性及增殖的影响[J].临床与实验病理学杂志,2016,32(4):405-412.
WANG LL,YANG WX,LI Y,et al.Effects of TNFAIP3 siRNA on NF-κB activity and proliferation of diffuse large B-cell lymphoma OCI-LY1 cells[J].Journal of Clinical and Experimental Pathology,2016,32(4):405-412.
[7] GUO T,ZHANG Y,QU X,et al.miR-200a enhances TRAIL-induced apoptosis in gastric cancer cells by targeting A20[J].Cell Biol Int,2018,42(5):506-514.
[8] IORGA A,DONOVAN K,SHOJAIE L,et al.Interaction of RIPK1 and A20 modulates MAPK signaling in murine acetaminophen toxicity[J].J Biol Chem,2021,296:100300.
[9] ISMAIL IH,GAGNEJ P,GENOIS MM,et al.The RNF138 E3 ligase displaces Ku to promote DNA end resection and regulate DNA repair pathway choice[J].Nat Cell Biol,2015,17(11):1446-1457.
[10] YU X,LI W,DENG Q,et al.MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis[J].Blood,2021,137(12):1615-1627.
[11] RAMCHANDREN R,JOHNSON P,GHOSH N,et al.The iR(2) regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL:A multicentre,non-randomised,open-label phase 2 study[J].EClinicalMedicine,2023,56:101779.
[12] KATO M,SANADA M,KATO I,et al.Frequent inactivation of A20 through gene mutation in B-cell lymphomas[J].Rinsho Ketsueki,2011,52(6):313-319.
[13] PAIK JH,GO H,NAM SJ,et al.Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma:an analysis according to immunohistochemical subgroups and rituximab treatment[J].Leuk Lymphoma,2013,54(9):1934-1941.
[14] MONCRIEFFE MC,BOLLSCHWEILER D,LI B,et al.MyD88 death-domain oligomerization determines myddosome architecture:implications for Toll-like receptor signaling[J].Structure,2020,28(3):281-289.
[15] 黄燕,章玉英,钟赟,等.弥漫大B细胞淋巴瘤不同免疫学分型的预后比较[J].江西医药,2018,53(08):788-791,817.
HUANG Y,ZHANG YY,ZHONG Y,et al.Prognosis comparison of different immunological types of diffuse large B-cell lymphoma[J].Jiangxi Medicine,2018,53(08):788-791,817.
[16] 柴晓菲,宋魏,孙淼淼,等.生发中心与非生发中心型弥漫大B细胞淋巴瘤的临床病理因素分析[J].中国实用医药,2016,11(20):20-21.
CHAI XF,SONG W,SUN MM,et al.Analysis of clinicopathological factors in germinal center and non-germinal center type diffuse large B-cell lymphoma[J].Chinese Practical Medicine,2016,11(20):20-21.
[17] 王平,杨文秀,周杰,等.弥漫大B细胞淋巴瘤中NF-κB/P65、PD-1、PD-L1 表达相关性研究及其蛋白表达的临床意义[J].中国癌症杂志,2020,30(5):375-382.
WANG P,YANG WX,ZHOU J,et al.Correlation between the expression of NF-κB/P65,PD-1 and PD-L1 in diffuse large B-cell lymphoma and its clinical significance[J].Chinese Journal of Cancer,2020,30(5):375-382.
[18] DIMOPOUL K,SOGAARD HELBO A,FIBIGER H,et al.Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myelomacells to IMiDs in a cereblon-independent manner[J].Mol Oncol,2018,12(2):180-195.
[19] MOONEY EC,SAHINGUR SE.The ubiquitin system and A20:Implications in health and disease[J].J Dent Res,2021,100(1):10-20.
[20] SOLOMON LA,BATISTA CR,DEKOTER RP.Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB[J].Exp Hematol,2017,56:46-57.